Literature DB >> 30604296

Expert's comment concerning Grand Rounds case entitled "Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation" by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8).

Anthony Todd1.   

Abstract

Entities:  

Year:  2019        PMID： 30604296     DOI： 10.1007/s00586-018-5843-2

Source DB:  PubMed          Journal:  Eur Spine J        ISSN： 0940-6719            Impact factor:   3.134


× No keyword cloud information.
  13 in total

1.  Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  James D Douketis; Alex C Spyropoulos; Frederick A Spencer; Michael Mayr; Amir K Jaffer; Mark H Eckman; Andrew S Dunn; Regina Kunz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.

Authors:  Harry R Büller; Martin H Prins; Anthonie W A Lensin; Hervé Decousus; Barry F Jacobson; Erich Minar; Jaromir Chlumsky; Peter Verhamme; Phil Wells; Giancarlo Agnelli; Alexander Cohen; Scott D Berkowitz; Henri Bounameaux; Bruce L Davidson; Frank Misselwitz; Alex S Gallus; Gary E Raskob; Sebastian Schellong; Annelise Segers
Journal:  N Engl J Med       Date:  2012-03-26       Impact factor: 91.245

3.  Guideline on the management of bleeding in patients on antithrombotic agents.

Authors:  Mike Makris; Joost J Van Veen; Campbell R Tait; Andrew D Mumford; Mike Laffan
Journal:  Br J Haematol       Date:  2012-11-01       Impact factor: 6.998

4.  Rivaroxaban-induced epidural hematoma and cauda equina syndrome after total knee arthroplasty: a case report.

Authors:  Kristen E Radcliff; Alvin Ong; Javad Parvizi; Zachary Post; Fabio Orozco
Journal:  Orthop Surg       Date:  2014-02       Impact factor: 2.071

Review 5.  Clinical review: Prothrombin complex concentrates--evaluation of safety and thrombogenicity.

Authors:  Benny Sørensen; Donat R Spahn; Petra Innerhofer; Michael Spannagl; Rolf Rossaint
Journal:  Crit Care       Date:  2011-01-12       Impact factor: 9.097

6.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

7.  Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Authors:  Matthew W Sherwood; James D Douketis; Manesh R Patel; Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Alex C Spyropoulos; Graeme J Hankey; Daniel E Singer; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Richard C Becker
Journal:  Circulation       Date:  2014-02-19       Impact factor: 29.690

8.  Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors.

Authors:  Stuart J Connolly; Truman J Milling; John W Eikelboom; C Michael Gibson; John T Curnutte; Alex Gold; Michele D Bronson; Genmin Lu; Pamela B Conley; Peter Verhamme; Jeannot Schmidt; Saskia Middeldorp; Alexander T Cohen; Jan Beyer-Westendorf; Pierre Albaladejo; Jose Lopez-Sendon; Shelly Goodman; Janet Leeds; Brian L Wiens; Deborah M Siegal; Elena Zotova; Brandi Meeks; Juliet Nakamya; W Ting Lim; Mark Crowther
Journal:  N Engl J Med       Date:  2016-08-30       Impact factor: 91.245

9.  Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.

Authors:  Ravi Sarode; Truman J Milling; Majed A Refaai; Antoinette Mangione; Astrid Schneider; Billie L Durn; Joshua N Goldstein
Journal:  Circulation       Date:  2013-08-09       Impact factor: 29.690

10.  Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.

Authors:  J H Levy; K T Moore; M D Neal; D Schneider; V S Marcsisin; J Ariyawansa; J I Weitz
Journal:  J Thromb Haemost       Date:  2017-12-02       Impact factor: 5.824
View more
  2 in total

1.  Expert's comment concerning Grand Rounds case entitled "Retroperitoneal haematoma in a postoperative ALIF patient taking rivaroxaban for atrial fibrillation" by Deekonda P, Stokes OM, Chan D (Eur Spine J [2016]: DOI 10.1007/s00586-016-4822-8).

Authors:  Anthony Todd
Journal:  Eur Spine J       Date:  2019-01-02       Impact factor: 3.134

2.  Rectus sheath hematoma and retroperitoneal bleeding due to rivaroxaban: a case report.

Authors:  Elif Börekci
Journal:  Afr Health Sci       Date:  2019-06       Impact factor: 0.927
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.